H1N1 (Swine Influenza) - Pipeline Assessment and Market Forecasts to 2017

London, United Kingdom (PressExposure) March 08, 2011 -- GlobalData estimated the H1N1 (swine influenza) therapeutics market was worth $6.77 billion in 2010. GlobalData expects the H1N1 (Swine Influenza) therapeutics market to decline at a Compound Annual Growth Rate (CAGR) of 4% from $6.77 billion in 2010 to $5 billion approximately in 2017. The negative growth is primarily due to the fact that the pandemic has now moved into the post-pandemic stage. In addition, the expiration of major drug patents, namely Tamiflu in 2016 and Relenza in 2013, are also going to have a negative impact on the growth of this market.

GlobalData found that the products currently in the market are highly efficacious in providing protection against the disease with minimum side-effects. All of the marketed products provide high seroprotection rates and seroconversion rates against the disease. The key products such as Fluzone, Fluvirin, Afluria and Flumist are able to satisfy the demand in the H1N1 swine influenza vaccines market. The key products such as Tamiflu (oseltamivir) and Relenza (zanamivir) are also able to satisfy the demand in the H1N1 swine influenza market.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=H1N1-%28Swine-Influenza%29-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

The H1N1 swine influenza therapeutics market has moderately low unmet needs as the market is well served by the current product options. This leaves little scope for new entrants to capture value from under-served segments. The new products have to aim at gaining market share by providing unique offerings. The likely untapped area is the availability of products with novel mechanisms of action.

approximately 22 molecules in various phases of clinical development, including five first-in-class molecules. These first-in-class molecules are in the early stages of clinical development, so their impact on the current market will be later in the future. In the case of vaccines, most of the late stage pipeline vaccines do not have novel mechanisms of action except for a single molecule which is in the early stage of development. As a result, the pipeline for the H1N1 (Swine Influenza) therapeutics market is weak.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=H1N1-%28Swine-Influenza%29-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare

Visit our report store: http://www.globaldata.com

About Globaldata

GlobalData's Report Store features thousands of high quality research reports across a broad range of industries. The reports draw on in-depth primary and secondary research, databases of proprietary in house data and high quality analysis from our expert teams. Data and analysis at the company, country and industry level includes competitors, valuations, trends, forecasts and analytics. Please feel free to browse our reports via the industry tabs below or alternatively contact us if you have any specific data requests or queries.


For more details contact:
pressreleases@globaldata.com
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782

Press Release Source: http://PressExposure.com/PR/Globaldata.html

Press Release Submitted On: March 08, 2011 at 5:23 am
This article has been viewed 28137 time(s).